ABSK-011

DRUG2 trials

Sponsors

Abbisko Therapeutics Co, Ltd, RenJi Hospital

Conditions

Advanced Liver CancerHCC - Hepatocellular Carcinoma

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

RecruitingNCT04906434

Abbisko Therapeutics Co, LtdAdvanced Liver Cancer

Start: 2020-02-26End: 2028-12-31Target: 200Updated: 2026-04-07

Phase 2

FGF19 Overexpression Combination Unified Study in HCC-19

RecruitingNCT06978933

RenJi HospitalHCC - Hepatocellular Carcinoma

Start: 2025-04-30End: 2027-12-31Target: 42Updated: 2025-05-18

Related Papers

First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.

2023-02-147 citations